Uses
Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Source: US FDA prescribing information
- Presentations
- 2
- Brands
- 0
- Manufacturers
- 0
- Available from stock
- 0
Amcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It is available as ointment and cream for topical use. MedsAcross supplies Amcinonide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Corticosteroid, Corticosteroid Hormone Receptor Agonists
- ATC classification
- D07AC11 Amcinonide · Corticosteroids for the skin, subgroup D07A, subgroup D07AC
- US FDA first approval
- 18 October 1979
- EU status
- Not recorded
- Orphan designation
- Not recorded
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Topical
- Dosage forms
- Ointment, Cream
- Identifiers
- UNII 423W026MA9RxCUI 17652CAS 51022-69-6DrugBank DB00288Q4742041
Clinical information
From the regulator-approved product information. Each section names its source.
Dosing overview
Topical corticosteroids are generally applied to the affected area as a thin film from two to three times daily depending on the severity of the condition. Occlusive dressings may be a valuable therapeutic adjunct for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Source: US FDA prescribing information
Contraindications
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Source: US FDA prescribing information
Warnings and precautions
General: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia and glucosuria in some patients. Conditions that augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA-axis suppression by using the urinary free-cortisol and ACTH stimulation tests. If HPA-axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute with a less potent steroid.
Source: US FDA prescribing information
Side effects
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.
Source: US FDA prescribing information
Storage
Store at controlled room temperature 15° - 30°C (59° - 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
2 presentations of Amcinonide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Amcinonide 0.1% ointmentTopicalGeneric name | — | US FDA | Available on request |
| Amcinonide 0.1% creamTopicalGeneric name | — | US FDA | Available on request |
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 18 October 1979 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions
Conditions linked to Amcinonide in public data. This is not a list of approved uses, see the clinical information.
Questions and answers
Is Amcinonide available for export from India?
Yes, on request. MedsAcross lists 2 presentations of Amcinonide and sources them for licensed hospitals, importers and physicians against valid import documents.
Is Amcinonide approved by the US FDA?
Yes. The US FDA first approved Amcinonide on 18 October 1979, according to Drugs@FDA.
Does Amcinonide need cold chain shipping?
No listed presentation of Amcinonide is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Amcinonide in?
Amcinonide is classified under ATC code D07AC11 (Amcinonide).
References
- Amcinonide prescribing information (Ayurax). U.S. National Library of Medicine, DailyMed. Retrieved 5 October 2026
Request Amcinonide for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.